# Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

> **NCT03422627** · PHASE1,PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 32 (actual)

## Conditions studied

- Chronic Graft Versus Host Disease cGVHD

## Interventions

- **DRUG:** Efavaleukin Alfa

## Key facts

- **NCT ID:** NCT03422627
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-27
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03422627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03422627, "Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03422627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*